In a report released yesterday, Silvan Tuerkcan from Oppenheimer assigned a Buy rating to Constellation Pharmaceuticals (CNST – Research Report), with a price target of $55.00. The company’s shares closed last Wednesday at $44.90.
According to TipRanks.com, Tuerkcan is a 5-star analyst with an average return of 38.4% and a 78.6% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Seattle Genetics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Constellation Pharmaceuticals with a $50.86 average price target, representing a 27.1% upside. In a report issued on April 28, RBC Capital also maintained a Buy rating on the stock with a $45.00 price target.
The company has a one-year high of $59.49 and a one-year low of $6.02. Currently, Constellation Pharmaceuticals has an average volume of 346.4K.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.